GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Bharat Biotech and GSK collaborate to develop a vaccine for Shigellosis, a severe form of bacterial diarrhea. The innovative ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...